Q3 2025 was a landmark quarter for rheumatology news, with both breakthrough United States Food and Drug Administration (FDA) approvals and pivotal trial results reshaping treatment options across autoimmune and inflammatory diseases. The FDA also expanded access to guselkumab for pediatric psoriasis and psoriatic arthritis (PsA), while golimumab showed promise as a steroid-sparing agent in early PsA. Dapirolizumab pegol (DZP) significantly improved disease activity and fatigue in systemic lupus erythematosus, while deucravacitinib moved closer to approval in psoriatic arthritis following a positive FDA review. Check out this Q3 2025 rheumatology month in review for a recap of HCPLive’s coverage of the top rheumatology news and research from the past few months:1. The siRNA therapy, given quarterly, demonstrated robust efficacy with manageable safety, positioning it for a planned BLA submission in early 2026.